Ruud Dings received his M.S. degree in biological health sciences specializing in tumor vascular immunology, from the University of Maastricht, The Netherlands, in 2000. He received his Ph.D. degree from the same institution in 2003, working jointly under the supervision of Professor Arjan W. Griffioen (Maastricht) and Prof. Kevin H. Mayo (University of Minnesota), studying drug discovery, design, and development in cancer with special interest in angiogenesis. Presently he is a Research Assistant Professor at the University of Minnesota investigating areas that are aimed at enhancing our understanding of cancer vascular biology to discover and develop improved methods for cancer treatment, including novel compounds as well as novel treatment strategies. Particular areas of interest are 1) the development of novel small molecules applicable in a range of different biological areas (anticancer, antiangiogenic, and antibacterial), 2) elucidating the angiostatic radio- and chemosensitization paradox by vessel normalization and tumor physiology, and 3) improvement of immunotherapy via tumor microenvironment modulation. His Key words include but are not limited to angiogenesis, tumor microenvironment, tumor immunology, galectins, radiation, thermal therapy vessel normalization, pericytes, translational research, angiogenesis inhibitors, combination therapies, drug discovery and development, and experimental oncology. He was a recipient of the AACR Scholar-in-Training Award (2002 and 2005), as well as the Michael A. O’Connor Young Investigator Award (2008). He is currently on the Editorial Boards of Angiogenesis and the International Journal of Biomedical Science.
Biography Updated on 9 August 2012